Recurrent nasopharynx carcinoma
Showing 1 - 25 of >10,000
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2022
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With
Completed
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +35 more
- PI3K inhibitor BKM120
- cetuximab
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Sep 14, 2021
Nasopharyngeal Carcinoma, De-escaltion Therapy Trial in Guangzhou (Reduced-target resection, Full-target resection, Adjuvant
Recruiting
- Nasopharyngeal Carcinoma
- De-escaltion Therapy
- Reduced-target resection
- +2 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 25, 2023
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors Trial (Cadonilimab, Gemcitabine, Cisplatin)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Immune Checkpoint Inhibitors
- Cadonilimab
- +2 more
- (no location specified)
Jun 1, 2023
Metastatic Urothelial Carcinoma Trial in Guangzhou (utidelone injection)
Recruiting
- Metastatic Urothelial Carcinoma
- utidelone injection
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
May 29, 2023
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- +2 more
- (no location specified)
May 14, 2023
Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Zanzalintinib
- +2 more
- (no location specified)
Oct 9, 2023
Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
- (no location specified)
Aug 17, 2023
Potential Chemoprevention Drugs in Recurrent Hepatocellular
Recruiting
- Hepatocellular Carcinoma Recurrent
- Surgery
- No intervention for research purpose
-
Taichung, TaiwanChina Medical University Hospital, Department of Surgery
Aug 5, 2023
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in United States
Not yet recruiting
- Adenoid Cystic Carcinoma
- +2 more
-
San Francisco, California
- +5 more
Nov 1, 2023
Recurrent Metastatic Nasopharyngeal Carcinoma Trial (Mitoxantrone HCl liposome injection, Capecitabine)
Not yet recruiting
- Recurrent Metastatic Nasopharyngeal Carcinoma
- Mitoxantrone hydrochloride liposome injection
- Capecitabine
- (no location specified)
Jan 29, 2023
Ovarian Clear Cell Carcinoma Trial (Zimberelimab, Metformin Hydrochloride)
Not yet recruiting
- Ovarian Clear Cell Carcinoma
- Zimberelimab
- Metformin Hydrochloride
- (no location specified)
Feb 25, 2023
Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Anrotinib plus Tirelizumab
-
Zhongshan, Guangdong, ChinaZhongshan City People's Hospital
Jul 31, 2023
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,
Not yet recruiting
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Ficlatuzumab
- +2 more
- (no location specified)
Sep 26, 2023
Nasopharyngeal Carcinoma, Maintenance Therapy Trial in Guangzhou (Capecitabine/Placebo combined with treprizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Maintenance Therapy
- Capecitabine/Placebo combined with treprizumab
-
Guangzhou, Guangdong, ChinaSunYat-senU
May 11, 2023
Hepatocellular Carcinoma Trial in United States (AZD5851)
Not yet recruiting
- Hepatocellular Carcinoma
- AZD5851
-
Duarte, California
- +9 more
Oct 12, 2023
Squamous Cell Carcinoma Trial (MK-3475A)
Not yet recruiting
- Squamous Cell Carcinoma
- MK-3475A
- (no location specified)
Sep 11, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)
Not yet recruiting
- Nasopharyngeal Carcinoma
- BL-B01D1
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 31, 2023
Pancreatic Carcinoma Trial in Shanghai (carbon ion radiotherapy)
Recruiting
- Pancreatic Carcinoma
- carbon ion radiotherapy
-
Shanghai, Shanghai, ChinaShanghai Proton and Heavy Ion Center
Apr 25, 2023
Following Salvage Surgery for RESidual or reCurrent sqUamous
Not yet recruiting
- Head and Neck Cancer
- Molecular Analyses
- (no location specified)
Mar 28, 2023
Basal Cell Carcinoma Trial in Maastricht (Punch biopsy (3mm))
Completed
- Basal Cell Carcinoma
- Punch biopsy (3mm)
-
Maastricht, Limbrug, NetherlandsMaastricht University Medical Center+
Oct 12, 2022
Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in
Recruiting
- Recurrent Endometrial Adenocarcinoma
- +8 more
- Ipilimumab
- Nivolumab
-
Iowa City, Iowa
- +9 more
Jan 27, 2023
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +3 more
- Pembrolizumab
- +3 more
-
Boston, Massachusetts
- +1 more
Feb 11, 2023
Recurrent Nasopharyngeal Carcinoma Trial (endoscopic surgery)
Not yet recruiting
- Recurrent Nasopharyngeal Carcinoma
- endoscopic surgery
- (no location specified)
Jun 22, 2022